Barrington Research upgraded shares of OPKO Health (NASDAQ:OPK – Free Report) from a market perform rating to an outperform rating in a report issued on Thursday morning, The Fly reports. The brokerage currently has $2.00 target price on the biotechnology company’s stock.
Other analysts have also recently issued reports about the company. HC Wainwright reaffirmed a buy rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Thursday, March 9th. StockNews.com cut OPKO Health from a hold rating to a sell rating in a research report on Thursday, June 15th. Finally, LADENBURG THALM/SH SH cut their price objective on OPKO Health from $5.75 to $5.40 in a research report on Thursday, May 4th.
OPKO Health Stock Performance
Shares of NASDAQ OPK opened at $1.96 on Thursday. The stock has a 50 day moving average price of $1.57 and a 200 day moving average price of $1.40. OPKO Health has a 52 week low of $1.00 and a 52 week high of $2.86. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.49 and a current ratio of 1.83. The stock has a market capitalization of $1.51 billion, a PE ratio of -5.14 and a beta of 1.66.
Insider Transactions at OPKO Health
In other news, insider Gary J. Nabel bought 187,608 shares of the stock in a transaction dated Friday, May 5th. The shares were bought at an average price of $1.81 per share, for a total transaction of $339,570.48. Following the completion of the purchase, the insider now owns 263,079 shares in the company, valued at $476,172.99. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 42.62% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On OPKO Health
Hedge funds have recently added to or reduced their stakes in the stock. Guggenheim Capital LLC bought a new position in OPKO Health during the 1st quarter worth $38,000. Point72 Hong Kong Ltd bought a new position in OPKO Health during the 1st quarter worth $39,000. Zacks Investment Management bought a new position in OPKO Health during the 3rd quarter worth $25,000. Beacon Pointe Advisors LLC acquired a new stake in shares of OPKO Health in the 1st quarter valued at $49,000. Finally, Verition Fund Management LLC acquired a new stake in shares of OPKO Health in the 2nd quarter valued at $36,000. Institutional investors own 23.49% of the company’s stock.
OPKO Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Further Reading
- Five stocks we like better than OPKO Health
- Is it Time To Ring The Register On Paychex?
- Micron Technology: A Reversal Is Imminent
- Can Topgolf Callaway Brands Crawl Out of the Bunker and Rally?
- McCormick Rebound Imminent: Executive Transition Complete
- 3 Reasons Boston Beer Stock Could Finally Hop Higher
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
